The VVL provides custom baculovirus, adenovirus, vaccinia virus, herpes, and other recombinant virus construction for heterologous gene expression, and vaccine and gene therapy studies. For the production of proteins in eukaryotic cells the laboratory uses recombinant baculoviruses-based expression in insect cell cultures.

The VVL is currently supported by a Louisiana Governor's Biotechnology Initiative Program Grant as a support facility for the construction of recombinant adenoviruses and herpes simplex viruses for cancer therapy. In addition, VVL is funded by NIH for the generation of vesicular stomatitis viruses as vaccine vectors for West Nile virus and simian retroviruses in collaboration with the Tulane National Primate Research Center in Covington, LA.

VVL provides technological and scale-up support services via direct contractual arrangements. For further information, contact Dr. Gus Kousoulas, BioMMED Director.